Chatham Capital Group Inc. Sells 736 Shares of Johnson & Johnson (NYSE:JNJ)

Chatham Capital Group Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,866 shares of the company’s stock after selling 736 shares during the quarter. Johnson & Johnson accounts for about 1.6% of Chatham Capital Group Inc.’s holdings, making the stock its 17th biggest holding. Chatham Capital Group Inc.’s holdings in Johnson & Johnson were worth $9,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. US Asset Management LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $30,000. Jackson Wealth Management LLC increased its holdings in Johnson & Johnson by 1.7% in the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after acquiring an additional 277 shares in the last quarter. Iron Horse Wealth Management LLC boosted its stake in Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Johnson & Johnson by 290.7% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock valued at $47,000 after acquiring an additional 218 shares during the last quarter. Finally, Strategic Asset Management LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $50,000. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE JNJ opened at $181.87 on Monday. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $183.19. The company has a quick ratio of 1.12, a current ratio of 1.35 and a debt-to-equity ratio of 0.41. The company’s fifty day moving average is $171.55 and its 200-day moving average is $167.30. The stock has a market cap of $478.18 billion, a price-to-earnings ratio of 23.32, a P/E/G ratio of 2.74 and a beta of 0.72.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, January 25th. The company reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.01. The company had revenue of $24.80 billion during the quarter, compared to analysts’ expectations of $25.29 billion. Johnson & Johnson had a return on equity of 37.46% and a net margin of 22.26%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.86 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.49 EPS for the current fiscal year.

Several equities analysts have issued reports on the company. The Goldman Sachs Group started coverage on Johnson & Johnson in a research note on Friday, December 17th. They issued a “neutral” rating and a $161.00 target price on the stock. Citigroup restated a “buy” rating and issued a $195.00 price objective (up from $192.00) on shares of Johnson & Johnson in a research report on Wednesday, December 15th. Bank of America began coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They set a “neutral” rating on the stock. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Finally, StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $180.29.

In other news, VP Thibaut Mongon sold 23,681 shares of the stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total value of $4,173,776.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.